

Dmitriy V Ivashchenko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3494538/publications.pdf>

Version: 2024-02-01

18
papers

125
citations

1683934

5
h-index

1281743

11
g-index

20
all docs

20
docs citations

20
times ranked

278
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects. <i>Frontiers in Physiology</i> , 2015, 6, 139.	1.3	64
2	Which cytochrome P450 metabolizes phenazepam? Step by step <i>in silico</i> , <i>in vitro</i> , and <i>in vivo</i> studies. <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 65-73.	0.3	10
3	CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 29-37.	0.4	10
4	Cognitive impairment in patients with treatment resistant schizophrenia: Associations with DRD2, DRD3, HTR2A, BDNF and CYP2D6 genetic polymorphisms. <i>Neurology Psychiatry and Brain Research</i> , 2019, 33, 48-55.	2.0	8
5	Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A <i>CYP2C19</i> gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 91-98.	0.3	6
6	Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation. <i>Drug Metabolism and Personalized Therapy</i> , 2020, 35, .	0.3	6
7	The Frequency of CYP2C9, VKORC1, and CYP4F2 Polymorphisms in Russian Patients With High Thrombotic Risk. <i>Medicina (Lithuania)</i> , 2013, 49, 81.	0.8	5
8	The association of polymorphisms in DAT (40â€‰bp VNTR, C>T 3â€‰UTR) and DBH (âˆ’1021 C/T) genes with the severe complications of alcohol withdrawal state. <i>Psychiatric Genetics</i> , 2015, 25, 268-269.	0.6	5
9	Supporting frontline clinicians in the time of the pandemic: Rapid response pharmacology team. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 725-729.	1.1	1
10	CYP2D6 phenotype and ABCB1 haplotypes are associated with antipsychotic safety in adolescents experiencing acute psychotic episodes. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .	0.3	1
11	Clinical pharmacology technologies for personalization of cardiovascular diseases drug treatment: focus on direct oral anticoagulants. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019, 74, 299-306.	0.2	1
12	Pharmacogenetic evaluation of adverse eventsâ€™ risk in patients with alcohol withdrawal syndrome taking bromdihydrochlorphenylbenzodiazepine: The role of CYP2C19 gene polymorphisms. <i>World Journal of Personalized Medicine</i> , 2017, 1, 18-26.	0.3	1
13	IMPACT OF CYP3A5, CYP2C9, CYP2C19, AND CYP2D6 POLYMORPHISMS ON PHENAZEPAM SAFETY IN PATIENTS WITH ALCOHOL WITHDRAWAL SYNDROME. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2018, 73, 206-214.	0.2	1
14	Pain pharmacogenetics. <i>Drug Metabolism and Personalized Therapy</i> , 2020, 35, .	0.3	1
15	Current and future use of umifenovir in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 75-80.	0.2	1
16	CYP2D6 phenotype and ABCB1 haplotypes are associated with antipsychotic safety in adolescents experiencing acute psychotic episodes. <i>Drug Metabolism and Personalized Therapy</i> , 2022, 37, 47-53.	0.3	1
17	Analysis of associations between pharmacodynamic genetic factors and antipsychoticsâ€™ effectiveness and safety in adolescents with acute psychotic episodes taking antipsychotics during a 28-day follow-up. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021, , 78-88.	0.2	0
18	Associations of CYP2D6, ABCB1 2677G>T/A and 3435C>T with effectiveness and safety of pharmacotherapy for acute psychotic episodes in adolescents over 28 days. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021, , 39-49.	0.2	0